Statins are commonly prescribed antilipidemic and anticholesterol class of drugs. In addition to their major role, they have been found to have anticancer effects on in vitro, animal and clinical studies. The aim of this study was to investigate the effects of six different statins (rosuvastatin, pravastatin, simvastatin, lovastatin, fluvastatin, and atorvastatin) on A549 cancer cells lipids by Fourier transform infrared (FTIR) spectroscopy. Proliferation tests were carried out to detect the half‐maximal inhibitory concentrations (IC₅₀) of each statin on A549 cells. The IC₅₀ values were 50 μM for simvastatin, 150 μM for atorvastatin and pravastatin, and 170 μM for fluvastatin, 200 μM for rosuvastatin and lovastatin on A549 cells. No correlation was found between the antiproliferative effects of the statins and lipid‐lowering effect. The cells were treated with IC₅, IC₁₀, and IC₅₀ values of each statins concentration and lipid extracts were compared using FTIR spectroscopy. The results indicated that different statins had different effects on the lipid content of A549 cells. The FTIR spectra of the lipid exctracts of statin‐treated A549 cells indicated that the value of hydrocarbon chain length, unsaturation index, oxidative stress level, and phospholipid containing lipids increased except for rosuvastatin‐treated A549 cells. In addition, rosuvastatin significantly lowered cholesterol ester levels. In conclusion, the contrasting effects of rosuvastatin should be further investigated.

中文翻译：

---

使用傅立叶变换红外光谱比较他汀类药物对 A549 非小细胞肺癌细胞系脂质的影响：瑞舒伐他汀脱颖而出

他汀类药物是常用的抗血脂和抗胆固醇类药物。除了它们的主要作用外，在体外、动物和临床研究中发现它们具有抗癌作用。本研究的目的是通过傅里叶变换红外 (FTIR) 光谱研究六种不同的他汀类药物（瑞舒伐他汀、普伐他汀、辛伐他汀、洛伐他汀、氟伐他汀和阿托伐他汀）对 A549 癌细胞脂质的影响。进行增殖试验以检测每种他汀类药物对 A549 细胞的半数最大抑制浓度 (IC ₅₀ )。IC ₅₀在 A549 细胞上，辛伐他汀为 50 μM，阿托伐他汀和普伐他汀为 150 μM，氟伐他汀为 170 μM，瑞舒伐他汀和洛伐他汀为 200 μM。未发现他汀类药物的抗增殖作用与降脂作用之间存在相关性。用IC ₅、IC ₁₀和IC ₅₀处理细胞使用 FTIR 光谱比较了每种他汀类药物浓度和脂质提取物的值。结果表明，不同他汀类药物对A549细胞脂质含量的影响不同。他汀处理的 A549 细胞脂质提取物的 FTIR 光谱表明，除瑞舒伐他汀处理的 A549 细胞外，烃链长度、不饱和指数、氧化应激水平和含磷脂的值均增加。此外，瑞舒伐他汀显着降低胆固醇酯水平。总之，应进一步研究瑞舒伐他汀的对比作用。